1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Amarin's REDUCE-IT Data For Vascepa May Be Game-Changing, But Not Without Controversy

 
• By Mandy Jackson

CVOT results for Amarin's fish-oil pill show an unprecedented reduction in cardiovascular deaths. While questions have been raised about an LDL increase in the placebo group, an investigator says the overall results are too good to be explained by a well-known mineral oil effect.

Human heart. 3d illustration.

Amarin Corp. PLC has the first successful cardiovascular outcomes trial for a drug added on to statin therapy in the REDUCE-IT trial of the company’s fish oil-derived Vascepa (icosapent ethyl), but an increase in LDL cholesterol in the placebo arm has raised some concern about the full data presented at the American Heart Association (AHA) annual meeting.

Vascepa, indicated for the treatment of hypertriglyceridemia, showed a 25% relative risk reduction in cardiovascular events in the outcomes trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Mineralys In The Money As Lorundrostat Gets Close To Market

 
• By Kevin Grogan

An upsized public offering will add $250m to the company’s coffers.

Cytokinetics’ Aficamten Shows Head-To-Head Advantage Vs. Beta Blockers

 
• By Joseph Haas

Awaiting US approval of aficamten in obstructive hypertrophic cardiomyopathy, Cytokinetics presented comparative data versus metoprolol that it hopes will be added to labeling later.

Ionis Looks Set To Own Its First Blockbuster

 
• By Jessica Merrill

Two Phase III trials testing Tryngolza for the treatment of severe hypertriglyceridemia hit investors’ bull case on efficacy.

More from Therapy Areas

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.